Cortexyme Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Cortexyme stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRTX, but not buy additional shares or sell existing shares.
View analyst ratings for Cortexyme or view top-rated stocks.

Wall Street analysts have given Cortexyme a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cortexyme wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cortexyme is scheduled to release its next quarterly earnings announcement on Monday, August 16th 2021.
View our earnings forecast for Cortexyme.

Cortexyme, Inc. (NASDAQ:CRTX) released its earnings results on Monday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by $0.08.
View Cortexyme's earnings history.

Cortexyme's stock was trading at $37.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRTX stock has increased by 45.1% and is now trading at $53.70.
View which stocks have been most impacted by COVID-19.

6 brokerages have issued twelve-month target prices for Cortexyme's stock. Their forecasts range from $20.00 to $76.00. On average, they expect Cortexyme's stock price to reach $43.33 in the next twelve months. This suggests that the stock has a possible downside of 19.3%.
View analysts' price targets for Cortexyme or view top-rated stocks among Wall Street analysts.

Some companies that are related to Cortexyme include Cerner (CERN), Omnicell (OMCL), Allscripts Healthcare Solutions (MDRX), Vocera Communications (VCRA), HealthStream (HSTM), Computer Programs and Systems (CPSI), Athena Technology Acquisition (ATHN) and Mirage Energy (MRGE).
View all of CRTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), DHT (DHT), EnLink Midstream (ENLC), Golar LNG Partners (GMLP), Matinas BioPharma (MTNB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Tilly's (TLYS).

(CRTX) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Cortexyme's stock is owned by many different retail and institutional investors. Top institutional shareholders include EPIQ Capital Group LLC (12.37%), Capital International Investors (8.32%), BlackRock Inc. (4.61%), Pacific Heights Asset Management LLC (0.93%), Geode Capital Management LLC (0.88%) and Northern Trust Corp (0.57%). Company insiders that own Cortexyme stock include Casey Lynch, David Lamond, Epiq Capital Group, Llc and Leslie Holsinger.
View institutional ownership trends for Cortexyme.

CRTX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Capital International Investors, Millennium Management LLC, Squarepoint Ops LLC, Goldman Sachs Group Inc., SG Americas Securities LLC, Cubist Systematic Strategies LLC, and Credit Suisse AG. Company insiders that have sold Cortexyme company stock in the last year include Casey Lynch, and Leslie Holsinger.
View insider buying and selling activity for Cortexyme or view top insider-selling stocks.

CRTX stock was acquired by a variety of institutional investors in the last quarter, including EPIQ Capital Group LLC, Citigroup Inc., Hennion & Walsh Asset Management Inc., Pacific Heights Asset Management LLC, Rafferty Asset Management LLC, UBS Group AG, Geode Capital Management LLC, and ICONIQ Capital LLC. Company insiders that have bought Cortexyme stock in the last two years include David Lamond, and Epiq Capital Group, Llc.
View insider buying and selling activity for Cortexyme or or view top insider-buying stocks.

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRTX stock can currently be purchased for approximately $53.70.

Cortexyme has a market capitalization of $1.59 billion. The biopharmaceutical company earns $-76,850,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis.

Cortexyme employs 37 workers across the globe.

The official website for Cortexyme is www.cortexyme.com.

Cortexyme is headquartered at 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080.

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at (650) 910-5717 or via email at [email protected]